The U.S. Food and Drug Administration (FDA) expanded the indication for Bristol Myers Squibb’s mavacamten (Camzyos) to ...

Learn how to manage sodium intake with obstructive hypertrophic cardiomyopathy, including risks of too much or too little, ...

The FDA approved a new indication for mavacamten, extending its approval to include certain pediatric patients with ...

Camzyos is the first cardiac myosin inhibitor approved for pediatric symptomatic obstructi ...

A new Yale-developed artificial intelligence (AI) platform can detect individuals at risk for amyloid cardiomyopathy, an ...

U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients ...

FDA broadened Camzyos use to symptomatic oHCM in adults and pediatric patients ≥30 kg, representing the first adolescent ...

Cardiomyopathy can be a diverse diagnosis. There are many different types -- some inherited, others due to injury to the heart, treatment side effects, pregnancy, and a range of other causes. The ...

The work builds on a mission to harness AI for improving diagnosis and treatment of diseases and more effectively identifying ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michelle M.

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical ...

Boost HCM ROI by prioritizing high-unmet non-obstructive disease, differentiated targeted therapies, label expansion, payer access and data-driven uptake strategies.Dublin, Oct. 01, 2026 (GLOBE ...